Birchview Capital’s Cardiol Therapeutics CRDL Stock Holding History

Birchview Capital’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$166K	Buy	+100,000	New	+$159K	0.1%	69

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.52B AUM 24.83% 1-Year Est. Return

Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $200B AUM 30.19% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return

Birchview Capital's CRDL Position: Q3 2026 in Review

Birchview Capital opened a new position in Cardiol Therapeutics (CRDL) in Q3 2026: 100,000 shares worth $166K. The stake represents 0.1% of the portfolio and ranks #69 among its holdings.

42 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

Birchview Capital held 100,000 shares of Cardiol Therapeutics worth $166K as of Q3 2026.
Cardiol Therapeutics was a new Birchview Capital position in Q3 2026.
Cardiol Therapeutics made up 0.1% of Birchview Capital's portfolio in Q3 2026, its #69 holding.
42 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on Birchview Capital's 13F filing for Q3 2026, filed 13 Nov 2026.